Note: Ingredients listed on restricted chemical lists
EC/CAS
9005-25-8
Name of the chemical
Starch
Concentration
N/A
General Information
Revision date
2024-11-07
Product name
Ramipril Capsules USP 2.5 mg, 5 mg,
Manufacturer Name
Lupin Limited
Icons in SDS
Company Information
company name
Lupin Limited
Hazard Codes
Hazard statements (CLP)
H361
Hazard statements
Code
Statements
H361
Suspected of damaging fertility or the unborn child
Section 2
SECTION 2: Hazards identification
Fire and Explosion Health Expected to be non-combustible. Ramipril is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). Ramipril capsules are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer ramipril capsules within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor. Do not co-administer ramipril with aliskiren: in patients with diabetes. Suspected of damaging fertility or the unborn child
Environmental hazards
No information is available about the potential of this product to produce adverse environmental effects.
